SCHEMBL6786453

SCHEMBL6786453

CCOC(=O)C(=O)Nc1cccc2cccnc12

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 4/20 0.60
KMT2A Q03164 4/20 0.60
GPR35 Q9HC97 1/20 0.59
MEN1 O00255 3/20 0.59
TDP1 Q9NUW8 2/20 0.58
SMN1; SMN2 Q16637 3/20 0.57
HPGD P15428 2/20 0.56
KDR P35968 2/20 0.56
HTT P42858 2/20 0.56
ALDH1A1 P00352 1/20 0.56
RAB9A P51151 3/20 0.55
HCRTR1 O43613 1/20 0.55
NPC1 O15118 2/20 0.54
MAPT P10636 2/20 0.54
LMNA P02545 1/20 0.54
TSHR P16473 1/20 0.54
CASP3 P42574 1/20 0.53
SENP8 Q96LD8 1/20 0.53
SENP7 Q9BQF6 1/20 0.53
SENP6 Q9GZR1 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1011405 0.86 KMT2A (0.63) POLBKMT2AMEN1TDP1SMN1; SMN2
SCHEMBL18415559 0.86 POLB (0.64) POLBKMT2AMEN1TDP1SMN1; SMN2
SCHEMBL16264456 0.81 GPR35 (0.67) POLBKMT2AGPR35MEN1SMN1; SMN2
SCHEMBL17237875 0.81 MAPT (0.62) POLBKMT2AMEN1TDP1SMN1; SMN2
SCHEMBL6785564 0.80 KMT2A (0.56) POLBKMT2AGPR35MEN1HPGD
SCHEMBL4832881 0.79 ALDH1A1 (0.54) POLBKMT2AMEN1TDP1SMN1; SMN2
SCHEMBL5326796 0.79 HDAC4 (0.67) POLBKMT2AMEN1TDP1HPGD
SCHEMBL8401892 0.79 TDP1 (0.73) POLBKMT2AMEN1TDP1SMN1; SMN2
SCHEMBL6985945 0.78 HPGD (0.57) POLBKMT2AMEN1TDP1SMN1; SMN2
SCHEMBL5328065 0.78 HDAC1 (0.69) POLBKMT2AMEN1TDP1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6703391-B2 THROMBOSIS, BRAIN DISORDERS, CARDIOVASCULAR DISORDERS, ALZHEIMER'S DISEASE, HUNTINGTON DISEASES NEUROSEARCH A/S (DK) 2004-03-09 US disclosed
US-20030114422-A1 NOVEL QUINOXALINEDIONE DERIVATIVES, THEIR PREPARATION AND USE NEUROSEARCH A/S (DK) 2003-06-19 US disclosed
EP-0664807-B1 QUINOXALINEDIONE DERIVATIVES AS EAA ANTAGONISTS WARNER LAMBERT CO (US) 1997-09-10 EP disclosed
EP-0664807-A1 QUINOXALINEDIONE DERIVATIVES AS EAA ANTAGONISTS. WARNER LAMBERT CO (US) 1995-08-02 EP disclosed
WO-1994009000-A1 QUINOXALINEDIONE DERIVATIVES AS EAA ANTAGONISTS WARNER-LAMBERT COMPANY (US) 1994-04-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030114422-A1 NOVEL QUINOXALINEDIONE DERIVATIVES, THEIR PREPARATION AND USE CHRNA3, CHRNA7, CHRNB3 POLB 2464/4885KMT2A 2162/4885GPR35 491/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.